Integra LifeSciences Holdings Corporation · NASDAQ:IART
Integra LifeSciences — Q2 2015 Earnings Presentation
23 slides from Integra LifeSciences's earnings presentation, Jul 30, 2015
Slide 1: Second Quarter 2015 Earnings Call Presentation
Second Quarter 2015 Earnings Call Presentation July 30, 2015
Slide 2: Forward-Looking Statements Safe Harbor and Non-GAAP Financial Measures
Forward-Looking Statements Safe Harbor and Non-GAAP Financial Measures Certain statements in this presentation that are not historical in nature are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, the statements related to expec
Slide 3: Notes Regarding Continuing Operations
Notes Regarding Continuing Operations • Beginning with third quarter 2015 results, Spine performance prior to July 1, 2015 will be reclassified as discontinued operations. • In the financial discussion today, we will discuss second quarter results including the performance of the Spine business. • F
Slide 4: Second Quarter 2015 Financial Highlights
Second Quarter 2015 Financial Highlights ($ millions) Q2 2015 Q2 2014 Change Revenue $ 244.1 $ 231.4 5.5% Organic Growth* 5.1% 3.9% 120 BPS Adj. EBITDA Margin* 20.7% 18.8% 190 BPS Adj. EPS* $ 0.79 $ 0.68 16.1% Cash Flows from Operations $ 18.1 $ 16.4 10.7% Free Cash Flow Conversion (TTM)* 54.0% 30.7
Slide 5: Long Term Strategy – Recent Accomplishments
Long Term Strategy – Recent Accomplishments Accelerate • Acquired TEI, expanding our regenerative technology portfolio, accelerating our DFU strategy, and entering adjacent markets Growth • Completed spin-off of SeaSpine, accelerating our top line and enabling more focus and growth investments in ne
Slide 6: Specialty Surgical Solutions Revenue Discussion
Specialty Surgical Solutions Revenue Discussion Specialty Surgical Solutions $146.7M; +6.7% • Dural repair sales increased mid-single digits • Precision Tools & Instruments increased low-single digits ex-MicroFrance Int’l: $40.2M; • Neuro Critical Care and Tissue Ablation declined +5.3% slightly as
Slide 7: Orthopedics and Tissue Technologies Revenue Discussion
Orthopedics and Tissue Technologies Revenue Discussion Orthopedics and Tissue Technologies $63.8M; +10.1% • Regenerative Technology sales increased in the high Int’l: teens $10.0M; (8.1%) • Upper Extremities sales increased strong double digits, led by new products in shoulder and wrist arthoplasty
Slide 8: Spine Revenue Discussion
Spine Revenue Discussion Spine $33.5M; -6.5% Int’l: $3.8M; • Spin completed July 1, 2015 8.2% • Global sales were up sequentially 4% • Orthobiologics sales were up low single digits • International sales were up high single digits U.S.: • Hardware sales were down double digits $29.7M; (8.2%) • SeaSp
Slide 9: 2015 Revenue Guidance: $870 million - $885 million
2015 Revenue Guidance*: $870 million - $885 million Change in 2015 Revenue Guidance from April Earnings Call: • No change to expectations for the base business $1,100 • Spine Spin-off: $1,000 $965-$980 Reduces revenue by $125- $130M on a C.O. basis, net TEI Fx $5 of supply agreements $900 $25-$30 $8
Slide 10: Components of Updated 2015 Revenue Guidance
Components of Updated 2015 Revenue Guidance* Components of Updated 2015 Revenue Guidance vs 2014: Full Year 2015: $1,000 • Full year organic growth: around 6% Acquired $900 $870-$885 • Acquisitions growth: Organic Fx Discontinued ~7.0% (includes partial year contributions from DuraSeal, ($ millions)
Slide 11: Operating Expenses: Second Quarter and YTD 2015 Results
Operating Expenses: Second Quarter and YTD 2015 Results Q2 Results June YTD Results Q2 Q2 YTD YTD % of revenue Change Change 2015 2014 2015 2014 Gross Margin 64.5% 62.4% 210 BPS 63.7% 62.1% 160 BPS Adj. Gross Margin* 67.7% 66.3% 140 BPS 67.1% 65.7% 140 BPS R&D 5.7% 5.9% (20 BPS) 5.5% 5.9% (40 BPS) S
Slide 12: Cash Flow and Other Measures: Second Quarter and YTD 2015 Results
Cash Flow and Other Measures: Second Quarter and YTD 2015 Results Q2 Results June YTD Results Q2 Q2 YTD YTD ($ Millions) Change Change 2015 2014 2015 2014 Oper. Cash Flow $ 18.1 $ 16.4 10.7% $ 49.7 $ 27.6 80.0% CapEx $ 13.1 $ 9.4 40.2% $ 22.0 $ 20.7 6.4% Free Cash Flow* $ 5.0 $ 7.0 -28.6% $ 27.7 $ 6
Slide 13: Continuing Operations Second Quarter Key Metrics
Continuing Operations* Second Quarter Key Metrics: ($ Millions) Q2 Results - C.O.* 2015 2014 Growth Revenue $ 212.1 $ 197.0 7.7% Organic Growth 7.1% N/A N/A Adj. EBITDA $ 47.5 $ 38.5 23.3% Adj. EBITDA Margin 22.4% 19.6% 280 BPS Adj. EPS $ 0.74 $ 0.61 21.5% *A reconciliation of amounts reclassified t
Slide 14: 2015 Guidance for Operating Expenses
2015 Guidance for Operating Expenses (% of revenue, $ Millions except per share amounts) 2015 Guidance 2014 FY C.O. Results Gross Margin* 63.5%-64.0% 62.0% Adj. Gross Margin 67.5%-68.0% 66.1% R&D ~5.5% 5.5% SG&A ~46.5% 47.1% Adj. SG&A ~42.5% 42.1% Adj. EBITDA 22.5%-23.0% 21.6% Depreciation ~$27 $23.
Slide 15: 2015 Adjusted EPS Guidance: $3.00 - $3.10
2015 Adjusted EPS Guidance*: $3.00 - $3.10 Change in 2015 Adj. EPS Guidance from April Earnings Call: No change to expectations $3.30 for the base business $3.15-$3.33 $3.20 TEI / Financing • Spine Spin-off: (neutral / Reduces adj. EPS by $3.10 slight acc.) $3.00-$3.10 $0.20 on a C.O. basis $3.00 Sp
Slide 16: Key Focus Areas For 2015 and Beyond
Key Focus Areas For 2015 and Beyond 1 Execute on our 2015 targets Complete spin-off of SeaSpine and integrate two-divisional global 2 structure 3 Invest in our channel strategy and new product introductions: • Introduce 4-5 substantial new products; drive +25% of organic growth • International expan
Slide 17: Appendix
Appendix Non-GAAP Reconciliations 17
Slide 18: Second Quarter and YTD 2015 and 2014 Organic Growth Reconciliation
Second Quarter and YTD 2015 and 2014 Organic Growth Reconciliation (In thousands) Q2 2015 Q2 2014 Jun YTD Jun YTD 2015 2014 Reported Revenue $244,078 $231,351 $477,743 $446,410 Revenues from discontinued products (2,407) (2,814) (4,713) (5,848) Revenue ex-discontinued products 241,671 228,537 473,03
Slide 19: Adjusted EBITDA Margin Reconciliation
Second Quarter and YTD 2015 and 2014 Adjusted EBITDA Margin Reconciliation Jun YTD Jun YTD (In thousands) Q2 2015 Q2 2014 2015 2014 GAAP net (loss)/income $ 4,998 $ 4,825 $ 13,382 $ 7,031 Depreciation and intangible asset amortization expense 15,745 15,203 31,159 29,164 Other (income) expense, net 9
Slide 20: Adjusted EPS Reconciliation
Second Quarter and YTD 2015 and 2014 Adjusted EPS Reconciliation Jun YTD Jun YTD (In thousands) Q2 2015 Q2 2014 2015 2014 GAAP net (loss) / income $ 4,998 $ 4,825 $ 13,382 $ 7,031 Manufacturing facility remediation costs - 224 - 367 Global ERP implementation charges 3,610 6,916 7,430 13,016 Structur
Slide 21: Free Cash Flow Conversion Reconciliation
Second Quarter 2015 and 2014 Free Cash Flow Conversion Reconciliation TTM TTM (In thousands) Q2 2015 Q2 2014 Q2 2015 Q2 2014 GAAP Net cash provided by operating activities $ 18,126 $ 16,377 $ 101,578 $ 70,135 Purchases of Property and Equipment $ (13,112) $ (9,356) $ (43,244) $ (44,067) Free Cash Fl
Slide 22: Adjusted Gross Margin Reconciliation
Second Quarter and YTD 2015 and 2014 Adjusted Gross Margin Reconciliation Jun YTD Jun YTD (In thousands) Q2 2015 Q2 2014 2015 2014 Reported Gross Profit $ 157,539 $ 144,375 $ 304,482 $ 277,051 Manufacturing facility remediation costs - 262 - 309 Structural optimization charges 2,047 2,467 3,927 4,17
Slide 23: Adjusted SG&A Reconciliation
Second Quarter and YTD 2015 and 2014 Adjusted SG&A Reconciliation Jun YTD Jun YTD (In thousands) Q2 2015 Q2 2014 2015 2014 Reported SG&A $ 126,590 $ 115,253 $ 240,654 $ 223,591 Manufacturing facility remediation costs - (38) - 58 Global ERP implementation charges 3,610 6,916 7,430 13,016 Structural
Integra LifeSciences Holdings — Q2 2015 Earnings Presentation on 6ix